Who are the luminaries driving the biggest advances in biopharma R&D? Endpoints News is asking for your nominations for a special report
In biopharma, driving a drug to market is the ultimate goal — but none of that happens without a strong research and development program. At the most successful companies, those R&D efforts are spearheaded by true innovators in the field who are always looking for that next novel mechanism of action or breakthrough safety profile.
Now, Endpoints News is asking you to tell us who those guiding lights are.
Endpoints will compile a list of the 20 most influential R&D executives in biopharma for a special report scheduled in August. While some of the longest-tenured and best-known R&D execs hold residence at the industry’s biggest companies, this isn’t just a showcase for Big Pharma — we’re looking for the movers and shakers at all levels of the industry.
So if you know a chief scientific officer, VP of translational research, head of oncology development or any position in between that deserves to be recognized, we ask you to submit their names and the reason why you’re nominating them to me at email@example.com or using this form.
This report is all part of Endpoints’ mission to showcase the best and brightest across the biopharma industry. Later this year, we’re planning our third annual Women in Biopharma report, spearheaded by senior editor Amber Tong and assistant editor Nicole DeFeudis. So please keep that in mind as well.
Meanwhile, so far this year we’ve rolled out our first-ever 60 Over 60 list, highlighting the long-tenured biopharma executives who have shaped the industry, as well as our 20 Under 40 list of the up-and-coming stars who will shape its future.
What else do we have in store? Just wait and see.